- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Steven Adelsheim Outlines Components of Screening for Psychosis in Young People
Early intervention in potential cases of psychosis among young people hinges on multiple settings being aware of the early signs of the illness and able to link people to treatment, said Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
Early intervention in potential cases of psychosis among young people hinges on multiple settings being aware of the early signs of the illness and able to link people to treatment, said Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
Transcript
What are the main components of programs that screen for early psychosis in young people?
So the main components of programs that identify young people early are really, first of all, having a sense of the early warning signs. Understanding that young people might become more avoidant of certain settings that they’ve traditionally been involved in, might be withdrawing from friends. Being able to have programs that can help people learn the early warning signs in schools, in juvenile justice settings, in primary care clinics, so that the people in those settings can learn that this might be what this young person is dealing with, whether they’re isolating more, having trouble paying attention, having changes in terms of even sounds or colors being different or brighter, and that all of those can be early signs of moving towards a psychotic process. So the most important part of screening, really, is helping the systems that a young person might be involved in understand that it’s important to recognize these signs and then link someone to service early.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More
